# Pathway Bioventures

Pathway Bioventures is a Venture Capital based in Chicago, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Chicago, United States
- **Region:** North America
- **Address:** 150 N. Riverside Plaza, Suite 2200, Chicago, IL 60606, United States
- **Founded:** 2018
- **Assets under management:** Undisclosed
- **Website:** www.pathwaybioventures.com
- **LinkedIn:** https://www.linkedin.com/company/pathwaybioventures

## Regulatory record

- **Reports private funds:** No

## About

Pathway Bioventures accelerates the growth of groundbreaking early-stage life sciences companies. The firm identifies new investment opportunities, conducts diligence, and provides portfolio company support. Its investment focus includes cancer epidemiology, genomics, and RNA therapeutics.

## Sectors

- Biotechnology
- Gene Therapy
- Cell Therapy
- RNA Therapeutics
- Genetic Medicine
- Precision Medicine

## People

- Daniel Jacobs — Founder & Managing Partner
- Matt Martin — Partner
- Jacob Segil — Venture Partner
- Marta New — Strategic Advisor
- David Hardwicke — Investment Consultant

## Questions

### Who runs investment decisions at Pathway Bioventures?

Founder and Managing Partner Daniel Jacobs leads all investment activities, including opportunity identification, diligence, and portfolio company support. He is supported by Partner Matt Martin, who brings 15 years of university, startup, and early-stage investment group management experience, and Venture Partner Jacob Segil. Strategic Advisor Marta New contributes immunology and biotech VC perspective from her time at Agent Capital and Baxter Ventures.

### How does Pathway Bioventures source proprietary deal flow?

The firm draws heavily on its principals' deep academic ties—Jacobs trained at Yale and Baylor, Martin at Carnegie Mellon and Los Alamos, Segil is a Research Professor at CU Boulder—to access university spinouts and research-stage therapeutics before they reach institutional Series A investors. Its team members' concurrent operating roles inside startups provide an additional embedded sourcing channel.

### Does Pathway participate in fund commitments or only direct deals?

Pathway makes direct seed-stage equity investments in therapeutics companies, co-investing within syndicates alongside other early-stage life-science investors. There is no indication the firm commits to external funds as a limited partner.

### What investment stages does Pathway Bioventures target?

The firm focuses on seed-stage companies and is explicit about supporting the transition from seed to Series A, helping portfolio companies build capital-efficient derisking strategies to attract later-stage biotech VCs and pharma corporate venture arms.

### Which sectors does Pathway Bioventures avoid?

Pathway's portfolio focuses exclusively on genetic medicine and molecularly-targeted precision therapeutics. It does not market activity in medical devices, diagnostics, health IT, or healthcare services, though Venture Partner Jacob Segil's personal work in neural interfaces sits outside the fund's stated genetic-medicine focus.

### How is Pathway Bioventures structured relative to its team's operating companies?

Several investment professionals simultaneously hold C-suite roles in portfolio or related companies: Matt Martin is CEO of Saros Therapeutics, a Pathway portfolio company; Jacob Segil is CEO of Afference; Marta New is CEO of CRO Radyus Research. This blurs the line between GP and operating executive, creating a model where diligence and company-building are performed by the same small group.

## Related profiles

- [Path Ventures](https://altss.com/profile/path-ventures)
- [Pathway Capital Management](https://altss.com/profile/pathway-capital-management)

---

Last updated: 2026-07-10T08:27:34.000Z

Canonical page: https://altss.com/profile/pathway-bioventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology